Exodus Point Capital Management, LP Aldeyra Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$6.11 - $8.16 $370,565 - $494,895	60,649 New	60,649 $405,000
Q1 2023 May 11, 2023	BUY	$5.77 - $9.93 $79,626 - $137,034	13,800 New	13,800 $137,000
Q3 2022 Nov 10, 2022	BUY	$3.8 - $7.74 $42,522 - $86,610	11,190 Added 49.74%	33,685 $180,000
Q2 2022 Aug 19, 2022	BUY	$2.43 - $4.85 $5,744 - $11,465	2,364 Added 11.74%	22,495 $90,000
Q1 2022 May 13, 2022	SELL	$3.25 - $5.17 $15,925 - $25,333	-4,900 Reduced 19.58%	20,131 $89,000
Q4 2021 Feb 11, 2022	SELL	$3.5 - $9.63 $19,120 - $52,608	-5,463 Reduced 17.91%	25,031 $100,000
Q3 2021 Nov 15, 2021	BUY	$7.94 - $11.31 $242,122 - $344,887	30,494 New	30,494 $268,000
Q2 2021 Aug 16, 2021	SELL	$10.44 - $14.85 $1.63 Million - $2.32 Million	-156,414 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $110,317 - $243,611	16,894 Added 12.11%	156,414 $1.86 Million
Q4 2020 Feb 16, 2021	BUY	$6.31 - $8.13 $808,298 - $1.04 Million	128,098 Added 1121.5%	139,520 $957,000
Q3 2020 Nov 16, 2020	SELL	$4.0 - $7.53 $6,652 - $12,522	-1,663 Reduced 12.71%	11,422 $85,000
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $25,777 - $66,079	13,085 New	13,085 $55,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.